Canada Life
MRNA icon

Canada Life’s Moderna MRNA Stock Holding History

Canada Life’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.6M Buy
152,228
+4,047
+3% +$209K 0.02% 516
2026
Q1 		$7.55M Buy
148,181
+5,792
+4% +$270K 0.01% 586
2025
Q4 		$4.2M Sell
142,389
-15,614
-10% -$424K 0.01% 819
2025
Q3 		$4M Buy
158,003
+8,106
+5% +$226K 0.01% 916
2025
Q2 		$4.14M Sell
149,897
-60,483
-29% -$1.59M 0.01% 878
2025
Q1 		$5.97M Buy
210,380
+3,881
+2% +$138K 0.01% 721
2024
Q4 		$8.58M Sell
206,499
-117
-0.1% -$5.59K 0.01% 606
2024
Q3 		$13.8M Buy
206,616
+10,640
+5% +$977K 0.02% 503
2024
Q2 		$23.3M Buy
195,976
+13,341
+7% +$1.69M 0.04% 362
2024
Q1 		$19.5M Sell
182,635
-71,912
-28% -$7.25M 0.04% 394
2023
Q4 		$25.2M Buy
254,547
+2,327
+0.9% +$196K 0.06% 320
2023
Q3 		$26.1M Buy
252,220
+49,347
+24% +$5.5M 0.06% 298
2023
Q2 		$24.8M Sell
202,873
-52,056
-20% -$6.94M 0.06% 312
2023
Q1 		$38.9M Buy
254,929
+25,231
+11% +$4.16M 0.1% 217
2022
Q4 		$41.4M Sell
229,698
-3,636
-2% -$595K 0.11% 199
2022
Q3 		$27.6M Buy
233,334
+30,473
+15% +$4.62M 0.08% 254
2022
Q2 		$29M Sell
202,861
-25,140
-11% -$3.59M 0.08% 261
2022
Q1 		$41.2M Sell
228,001
-14,203
-6% -$2.39M 0.09% 241
2021
Q4 		$61.4M Sell
242,204
-11,925
-5% -$3.49M 0.13% 166
2021
Q3 		$98.5M Buy
254,129
+35,018
+16% +$12.9M 0.23% 82
2021
Q2 		$51.5M Buy
219,111
+89,854
+70% +$16.1M 0.12% 185
2021
Q1 		$16.8M Buy
129,257
+8,716
+7% +$1.26M 0.04% 430
2020
Q4 		$12.5M Buy
120,541
+9,303
+8% +$941K 0.02% 539
2020
Q3 		$7.86M Buy
111,238
+51,784
+87% +$3.61M 0.02% 597
2020
Q2 		$3.8M Buy
+59,454
New +$3.26M 0.01% 778

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Canada Life's MRNA Position: Q2 2026 in Review

Canada Life increased its Moderna (MRNA) stake by 2.7% in Q2 2026, buying an estimated $209K and bringing the position to 152,228 shares worth $10.6M. The position accounts for 0.02% of the portfolio, ranked #516.

Canada Life first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $98.5M in Q3 2021. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Canada Life held 152,228 shares of Moderna worth $10.6M as of Q2 2026.
  • Canada Life bought 4,047 Moderna shares in Q2 2026, an estimated $209K.
  • Moderna made up 0.02% of Canada Life's portfolio in Q2 2026, its #516 holding.
  • Canada Life first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • Canada Life's Moderna position peaked at $98.5M in Q3 2021.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Canada Life's 13F filing for Q2 2026, filed 13 Aug 2026.